UBE2T Regulates FANCI Monoubiquitination to Promote NSCLC Progression by Activating EMT

Jiguang Zhang, Jingdong Wang, Jincheng Wu, Jianyuan Huang, Zhaoxian Lin, Xing LinResearch 2021 · DOI

Abstract

Background: Fanconi anemia complementation group I (FANCI) acts as a critical protein factor for maintaining DNA stability. However, the roles of FANCI in tumors have not been well revealed. In the current study, we aimed to explore the function and potential mechanism of FANCI in non-small-cell lung cancer (NSCLC).

Methods: To detect the expression of FANCI and UBE2T in NSCLC tissues, quantitative reverse-transcription PCR (qRT-PCR) and Western blot assays were employed. CCK-8, wound healing, Transwell, flow cytometry analysis, and tumor xenograft were used to investigate the biological effects of FANCI in NSCLC in vitro and in vivo. FANCI binding with UBE2T was confirmed using a co-immunoprecipitation (co-IP) assay. EMT protein markers were detected via Western blot.

Results: FANCI was upregulated in NSCLC tumor tissues compared with adjacent normal tissues. In A549 and H1299 cells, knockdown of FANCI inhibited cell growth, migration, invasion, and cell cycle, as well as epithelial-to-mesenchymal transition (EMT) in vitro. In vivo, tumor growth was also repressed when FANCI was downregulated. Mechanistically, UBE2T directly bound with FANCI and regulated the monoubiquitination of FANCI. Furthermore, UBE2T restored the inhibitory effects induced by knocking down FANCI in NSCLC cells.

Conclusion: FANCI is a putative oncogene in NSCLC and is monoubiquitinated by UBE2T to regulate cell growth, invasion, and migration. Our findings suggest that FANCI might be applied as a predictive biomarker and therapeutic target for NSCLC.

Introduction

Non-small-cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide. While targeted therapies against specific mutations have improved outcomes, many patients still face incurable disease due to late-stage diagnosis and drug resistance.

The researchers focused on FANCI (Fanconi anemia complementation group I), a protein traditionally known for its role in maintaining DNA stability and repairing interstrand cross-links. While its role in rare genetic diseases is well-documented, its specific contribution to the progression of common solid tumors like NSCLC has been largely unknown. This study aims to uncover how FANCI is regulated and how it contributes to the aggressive behavior of lung cancer cells.

Methods and Materials

The study employed a comprehensive suite of molecular biology techniques to bridge the gap between clinical observation and mechanistic proof. Researchers compared 32 pairs of fresh NSCLC tumor tissues against adjacent normal tissues collected at Fujian Provincial Hospital (2016–2020). Five NSCLC lines (H1650, H1975, H827, A549, H1299) and one normal human bronchial epithelial line (HBE) were utilized for in vitro analysis.

To quantify gene expression, qRT-PCR was performed using specific primer sequences for the target genes and internal controls.

Table 1: Primer sequences for FANCI, UBE2T, and β-actin used in qRT-PCR analysis.

Using NSCLC cell lines, the team performed "knockdown" experiments (using shRNA) to observe the effects of FANCI depletion on cell growth (CCK-8), migration (wound healing), and invasion (Transwell assays). Protein interactions were confirmed using Co-Immunoprecipitation (Co-IP) and RIP assays. Finally, findings were validated in vivo by injecting modified cancer cells into nude mice to observe tumor xenograft growth over five weeks.

Key Results

FANCI as an Oncogenic Driver

FANCI was significantly upregulated in both NSCLC tissues and cell lines compared to normal controls. Knocking down FANCI led to a dramatic reduction in cell proliferation and a significant increase in apoptosis (programmed cell death). Furthermore, reducing FANCI levels effectively slowed the cells' ability to migrate and invade, suggesting a decrease in metastatic potential.

The UBE2T-FANCI Axis and EMT Activation

A critical finding of this study is that UBE2T (an E2 ubiquitin-conjugating enzyme) performs monoubiquitination on FANCI. Rather than tagging the protein for destruction, this process stabilizes FANCI. This stabilization directly links the FA pathway to the Epithelial-Mesenchymal Transition (EMT). High levels of FANCI correlate with a decrease in epithelial markers (E-cadherin) and an increase in mesenchymal markers (N-cadherin, Vimentin), effectively "reprogramming" cells for mobility and invasion.

In Vivo Validation and Rescue

Mice injected with FANCI-depleted cells developed significantly smaller and lighter tumors compared to control groups. Crucially, overexpressing UBE2T was shown to reverse the inhibitory effects of a FANCI knockdown, proving that these two proteins work in the same functional pathway to drive cancer progression.

Discussion and Conclusion

This study identifies FANCI as a significant oncogenic driver in NSCLC, regulated post-translationally by UBE2T. The UBE2T-FANCI-EMT axis provides a new framework for understanding lung cancer metastasis.

While the link to EMT is established, the authors acknowledge that the exact signaling intermediates between FANCI monoubiquitination and the transcription factors triggering EMT remain to be fully mapped. Additionally, while the clinical data is compelling, larger cohorts are needed to confirm FANCI's reliability as a clinical biomarker. Ultimately, these findings suggest that disrupting the UBE2T-FANCI interaction could serve as a novel therapeutic strategy for treating aggressive NSCLC.

Summary updated

Abstract

Abstract Background: Fanconi anemia complementation group I (FANCI) acts as a critical protein factor for maintaining DNA stability. However, roles of FANCI in tumors has not been well revealed. In current study, we aimed to explore the function and potential mechanism of FANCI in non-small-cell lung cancer (NSCLC). Methods: To detect the expression of FANCI and UBE2T in NSCLC tissues, quantitative reverse-transcription PCR (qRT-PCR) and Western blot assays were employed. CCK-8, wound healing, Transwell, flow cytometry analysis and tumor xenograft were used to investigate the biological effects of FANCI in NSCLC in vitro and in vivo. FANCI binds with UBE2T was confirmed using coimmunoprecipitation (co-IP) assay. The EMT protein markers were detected via Western blot. Results: FANCI was upregulated in NSCLC tumor tissues compared with adjacent. In A549 and H1299 cells, knockdown of FANCI inhibited cell growth, migration, invasion and cell cycle,as well as epithelial-to-mesenchymal transition (EMT) in vitro. In vivo, the tumor growth was also repressed when FANCI was downregulated. Mechanistically, UBE2T directly bound with FANCI and regulated the monoubiquitination of FANCI. Futhermore, UBE2T restored the inhibitory effects induced by knocking down FANCI in NSCLC cells. Conclusion: FANCI was a putative oncogene in NSCLC, and was monouniubiquitinated by UBE2T to regulate cell growth, invasion and migration. Our findings suggested that FANCI might applied as a predicted biomarker and therapeutic target for NSCLC.
BibTeX
@inproceedings{zhang2021ube,
  author = {Jiguang Zhang and Jingdong Wang and Jincheng Wu and Jianyuan Huang and Zhaoxian Lin and Xing Lin},
  title = {{UBE2T Regulates FANCI Monoubiquitination to Promote NSCLC Progression by Activating EMT}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-977052/v1},
}
Figure